Sunday, December 9 - Plenary Sessions and Scientific Presentations

OncoLink Team (Carolyn Coyle MSN, RN, OCN, James Metz, MD,
Maggie Hampshire, RN, BSN, OCN)

Changes in Endogenous Erythropoietin and the Pharmacokinetics of Darbepoetin Alfa in Patients with Non-myeloid Malignancies Receiving or Not Receiving Chemotherapy Characterization of Erythroid Differentiation Related Factor (EDRF), a GATA-1 Regulated Molecular Chaperone for á-globin Protein Combining an Allogeneic Graft-Vs-Myeloma Effect with High-Dose Autologous Stem Cell Rescue in the Treatment of Multiple Myeloma Darbepoetin Alfa Administered Every 1 or 2 Weeks Alleviates Anemia in Patients With Solid Tumors Development and Validation of the FACT-Neutropenia Dose Response of Darbepoetin Alfa Is Similar in Anemic Patients with Solid Tumors or Lymphoproliferative Malignancies. Expression Profiling of Pediatric Acute Lymphoblastic Leukemia (ALL) Blasts at Diagnosis Accurately Predicts both the Risk of Relapse and of Developing Therapy-Induced ALL HRI is necessary for Regulation of Globin Translation and Survival of Erythroid Precursors in Iron-Deficiency Molecular and Chromosomal Characterization of Resistance in CML Patients after STI-571 (Glivec) Therapy Monitoring the Anti-Tumor Activity of Expanded CD8+ NKT Cells After Allogeneic Bone Marrow Transplantation Using Bioluminescent Imaging Structure of a von Willebrand Factor Cleaving Protease, an ADAMTS Protease Involved in Thrombotic Thrombocytopenic Purpura (TTP) The Epidemiology and Economics of Neutropenia in Hospitalized Adult Cancer Patients: Data From the University HealthSystem Consortium The Pharmacokinetics of Darbopoetin Alpha Administered Subcutaneously in Patients with Non-Myeloid Malignancies Receiving Multicycle Chemotherapy


Click on any of these terms for more related articles


My Cancer Experience
by Bob Riter
October 06, 2015

Related News

AHA: Increased Cancer Risk for Patients With Heart Failure

Nov 8, 2012

For patients with heart failure, incident cancer correlates with increased risk of death

AHA: Ideal Cardiovascular Health Tied to Cancer Risk

Nov 17, 2011

The number of ideal cardiovascular health metrics correlates inversely with cancer incidence

Diagnosis of any cancer for up to 10 years does not differ between statin and non-statin users

Nov 18, 2010

Diagnosis of any cancer for up to 10 years does not differ between statin and non-statin users